Potential beneficial impacts of tadalafil on cardiovascular diseases-Reference-Cited by-同舟云学术

Potential beneficial impacts of tadalafil on cardiovascular diseases

Published:2025-01-10 Issue:4 Volume:88 Page:267-272
ISSN:1726-4901
Container-title:Journal of the Chinese Medical Association
language:en
Short-container-title:

Author:

Lan Tien-Yun¹,Chiang Chih-Hung²³,Chen Jaw-Wen¹⁴⁵⁶⁷,Chang Ting-Ting¹⁴⁸

Affiliation:

1. Department and Institute of Pharmacology, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC

2. Division of Urology, Department of Surgery and Department of Research and Development, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan, ROC

3. Department of Urology, National Taiwan University Hospital, Taipei, Taiwan, ROC

4. Cardiovascular Research Center, Taipei Medical University Hospital, Taipei, Taiwan, ROC

5. Division of Cardiology, Taipei Medical University Hospital, Taipei, Taiwan, ROC

6. Faculty of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan, ROC

7. Cardiovascular Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC

8. Ph.D. Program of Interdisciplinary Medicine and Biomedical Industry, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC

Abstract

Tadalafil is a selective phosphodiesterase type 5 (PDE5) inhibitor commonly used for the treatment of erectile dysfunction and benign prostatic hyperplasia. Its mechanism of action involves the inhibition of PDE5, leading to increased levels of nitric oxide and cyclic guanosine monophosphate in the corpus cavernosum, which facilitates smooth muscle relaxation. This article reviews studies using tadalafil in the treatment of cardiovascular diseases and emphasizes its potential advantages in conditions such as pulmonary arterial hypertension, atherosclerosis, coronary artery disease, myocardial infarction, heart failure, stroke, diabetic ulcers, and cardiomyopathy. Although tadalafil shows potential efficacy in treating cardiovascular disease, further experimental studies are needed to clarify its pharmacological effects on cardiovascular protection beyond PDE5 inhibition.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference55 articles.

1. Review of the use of tadalafil in the treatment of benign prostatic hyperplasia in men with and without erectile dysfunction.;Hatzimouratidis;Ther Adv Urol,2014

2. Long-term effects of phosphodiesterase-5 inhibitors on cardiovascular outcomes and death: a systematic review and meta-analysis.;Soulaidopoulos;Eur Heart J Cardiovasc Pharmacother,2024

3. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk.;Rosano;Eur Urol,2005

4. The NO/cGMP/PKG pathway in platelets: the therapeutic potential of PDE5 inhibitors in platelet disorders.;Degjoni;J Thromb Haemost,2022

5. Phosphodiesterase 5 (PDE5): structure-function regulation and therapeutic applications of inhibitors.;Ahmed;Biomed Pharmacother,2021